2024
Treatment of prolonged drug reaction with eosinophilia and systemic symptoms syndrome with dupilumab using a molecularly-guided approach
Valido K, Patel V, Murphy M, Junejo M, Patel D, Deutsch A, Turner N, Zaki T, King B, Damsky W, Nelson C. Treatment of prolonged drug reaction with eosinophilia and systemic symptoms syndrome with dupilumab using a molecularly-guided approach. JAAD Case Reports 2024, 48: 49-53. PMID: 38774671, PMCID: PMC11107093, DOI: 10.1016/j.jdcr.2024.03.020.Peer-Reviewed Original Research
2023
Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management
Wei B, Fox L, Kaffenberger B, Korman A, Micheletti R, Mostaghimi A, Noe M, Rosenbach M, Shinkai K, Kwah J, Phillips E, Bolognia J, Damsky W, Nelson C. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management. Journal Of The American Academy Of Dermatology 2023, 90: 911-926. PMID: 37516356, DOI: 10.1016/j.jaad.2023.02.073.Peer-Reviewed Original ResearchSevere cutaneous adverse reactionsCutaneous adverse reactionsSystemic symptomsDrug reactionsAdverse reactionsDifferential diagnosisDrug-induced hypersensitivity syndrome/drug reactionDrug-induced hypersensitivity syndromeDiHS/DRESSVisceral organ involvementSteroid-sparing agentCornerstone of managementFirst-line therapyEvidence-based overviewSystemic corticosteroidsHypersensitivity syndromeImmediate discontinuationOrgan involvementRisk stratificationAutoimmune diseasesAdjunctive testNeoplastic disordersDiagnostic criteriaLongitudinal evaluationDiagnosisDrug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis
Wei B, Fox L, Kaffenberger B, Korman A, Micheletti R, Mostaghimi A, Noe M, Rosenbach M, Shinkai K, Kwah J, Phillips E, Bolognia J, Damsky W, Nelson C. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis. Journal Of The American Academy Of Dermatology 2023, 90: 885-908. PMID: 37516359, DOI: 10.1016/j.jaad.2023.02.072.Peer-Reviewed Original ResearchSevere cutaneous adverse reactionsDiHS/DRESSClinicopathological featuresSystemic symptomsDrug reactionsDrug-induced hypersensitivity syndrome/drug reactionDrug-induced hypersensitivity syndromePart I. EpidemiologyVisceral organ involvementCutaneous adverse reactionsRisk of relapseHypersensitivity syndromeOrgan involvementI. EpidemiologyOrgan dysfunctionSignificant morbidityAutoimmune diseasesAdverse reactionsDrug exposureT cellsCommon triggerImmune systemPathogenesisEosinophiliaMedical education activities